Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres

Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1–3). Side effects of alemtuzu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Trindade, Anil J., Thaniyavarn, Tany, Townsend, Keri, Klasek, Robin, Tsveybel, Karen P., Kennedy, John C., Goldberg, Hilary J., El-Chemaly, Souheil
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2020
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270280/
https://ncbi.nlm.nih.gov/pubmed/32547557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01063
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia